Spectris (SXS) Q2 2025 earnings summary

Executive summary

• Reported sales grew 8% year-over-year to £636.1m in H1 2025, with Q2 sales up 20% and order momentum improving, especially in the Scientific segment.

• Adjusted operating profit rose 7% to £65.6m, with strong cash conversion at 126%.

• Integration of 2024 acquisitions (SciAps, Micromeritics, Piezocryst, MicroMaritima, SIAP, PA Midcrest) is progressing well, with synergies exceeding expectations.

• Profit Improvement Programme set to deliver over £30m in savings for 2025, with most savings in H2.

• KKR's recommended cash acquisition offer at £41.75 per share, a 104.9% premium, includes a 28.0p interim dividend.

Financial highlights

• Orders up 5% reported (-2% LFL) in H1; Q2 orders up 15% (4% LFL); book-to-bill ratio just over 1x.

• Adjusted operating margin stable at 10.3%; statutory operating profit at £24.8m; gross margin at 54.6%.

• Adjusted EPS declined to 38.4p due to higher finance costs; statutory EPS was 5.3p.

• Adjusted cash flow conversion improved to 126%, driven by better working capital management.

• Net debt at £545.7m, leverage at 2.3x, with expectations to return to 1-2x range by year-end.

Outlook and guidance

• Over £30m in cost savings expected for 2025, with two-thirds to be realized in H2.

• H2 profit expected to benefit from higher order intake and acquisition contributions.

• Adjusted operating profit expected to be in line with management expectations.

• Focus remains on deleveraging and working capital improvement, aiming for leverage within 1x-2x by year-end.

• Long-term confidence underpinned by strategic investments and positioning in high-growth markets.